{
    "clinical_study": {
        "@rank": "157955", 
        "arm_group": [
            {
                "arm_group_label": "Medium Dose", 
                "arm_group_type": "Experimental", 
                "description": "Patients are treated with prednisone or equivlent at doseage of 0.5-0.6 mg/kg/d (max 40mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months."
            }, 
            {
                "arm_group_label": "High Dose", 
                "arm_group_type": "Experimental", 
                "description": "Patients are treated with prednisone or equivlent at doseage of 0.8-1.0 mg/kg/d (max 60mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, open-label, single-center clinical trial to compare the efficacy and\n      safety profile for medium-dose versus high dose glucocorticoid in patients with IgG4-related\n      Disease. Patients will be followed for three months to measure the primary outcome and\n      secondary outcomes."
        }, 
        "brief_title": "Glucocorticoids in Patients With IgG4-RD", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "IgG4-related Disease", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females\n\n          -  Age 18-70 years old with informed consent\n\n          -  Patients with IgG4-RD:\n\n               1. swelling, sclerosing and inflammatory involvement of one or more organ,\n                  including sclerosing pancreatitis, sclerosing cholangitis, inflammatory\n                  pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis,\n                  hypophysitis, sclerosing dacryoadenitis, sialadenitis, inflammatory aortic\n                  aneurysm, lymphadenopathy, or other inflammatory conditions;\n\n               2. elevated serum IgG4 (>1.35 g/L)\n\n               3. histopathologic features of fibrosis and/or lymphocytic and polyclonal plasma\n                  cell infiltration (and IgG4+ plasma cells on immunohistology when performed);\n\n               4. exclusion of other diseases.\n\n        Exclusion Criteria:\n\n          -  Previously or currently received glucocorticoid and(or) immunomodulator\n\n          -  Pregnancy or lactating\n\n          -  Concurrent severe and/or uncontrolled and/or unstable diseases\n\n          -  Patient with malignancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01758393", 
            "org_study_id": "PUMCH-GC-IgG4RD"
        }, 
        "intervention": {
            "arm_group_label": [
                "Medium Dose", 
                "High Dose"
            ], 
            "intervention_name": "Prednisone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Glucocorticoids", 
                "Prednisone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "IgG4-related disease", 
            "IgG4-RD"
        ], 
        "lastchanged_date": "December 24, 2012", 
        "location": {
            "contact": {
                "email": "zhangwen91@sina.com", 
                "last_name": "Wen Zhang, MD", 
                "phone": "+86-10-69158795"
            }, 
            "contact_backup": {
                "email": "chenhua@pumch.cn", 
                "last_name": "Hua Chen, MD", 
                "phone": "+86-10-69158797"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100032"
                }, 
                "name": "Deptment of Rheumatology, Peking Union Medical College Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Trial of Glucocorticoids in Patients With IgG4-Related Disease", 
        "overall_contact": {
            "email": "chenhua@pumch.cn", 
            "last_name": "Hua Chen, MD", 
            "phone": "+86-10-69158797"
        }, 
        "overall_official": [
            {
                "affiliation": "Deptment of Rheumatology, Peking Union Medical College Hospital", 
                "last_name": "Wen Zhang, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Deptment of Rheumatology, Peking Union Medical College Hospital", 
                "last_name": "Fengchun Zhang", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: National Natural Science Foundation", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Complete Response(CR) is defined as resolution of clinical manifestations, biochemical tests (C-reactive Proteins and IgG or IgG4 levels), and imaging studies.", 
            "measure": "Complete Response", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01758393"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking Union Medical College Hospital", 
            "investigator_full_name": "Wen Zhang", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Disease Response is measured by IgG4-RD Responder Index(IgG4-RD RI) and defined as:\nImprovement of > 2 points in the IgG4-RD RI over baseline\nNo disease flares, as assessed by the IgG4-RD RI.", 
                "measure": "Disease Response", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Treatment-related adverse effect, including glucocorticoid-induced diabetes mellitus and infections.", 
                "measure": "Adverse Effect", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Peking Union Medical College Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking Union Medical College Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}